BridgeBio Pharma Statistics
Share Statistics
BridgeBio Pharma has 189.88M
shares outstanding. The number of shares has increased by 1.64%
in one year.
| Shares Outstanding | 189.88M |
| Shares Change (YoY) | 1.64% |
| Shares Change (QoQ) | 0.63% |
| Owned by Institutions (%) | 93.73% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 40 |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 22.31M, so 11.73% of the outstanding
shares have been sold short.
| Short Interest | 22.31M |
| Short % of Shares Out | 11.73% |
| Short % of Float | 17.95% |
| Short Ratio (days to cover) | 7.35 |
Valuation Ratios
The PE ratio is -9.53 and the forward
PE ratio is -14.36.
BridgeBio Pharma's PEG ratio is
0.35.
| PE Ratio | -9.53 |
| Forward PE | -14.36 |
| PS Ratio | 23.01 |
| Forward PS | 3.1 |
| PB Ratio | -3.5 |
| P/FCF Ratio | -9.79 |
| PEG Ratio | 0.35 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for BridgeBio Pharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.67,
with a Debt / Equity ratio of -1.19.
| Current Ratio | 4.67 |
| Quick Ratio | 4.67 |
| Debt / Equity | -1.19 |
| Debt / EBITDA | -3.96 |
| Debt / FCF | -3.32 |
| Interest Coverage | -5.97 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $306,071.72 |
| Profits Per Employee | $-738,982.07 |
| Employee Count | 725 |
| Asset Turnover | 0.24 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 1.15M |
| Effective Tax Rate | -0.21% |
Stock Price Statistics
The stock price has increased by 35.81% in the
last 52 weeks. The beta is 1.15, so BridgeBio Pharma's
price volatility has been higher than the market average.
| Beta | 1.15 |
| 52-Week Price Change | 35.81% |
| 50-Day Moving Average | 34.3 |
| 200-Day Moving Average | 29.35 |
| Relative Strength Index (RSI) | 64.57 |
| Average Volume (20 Days) | 3,582,713 |
Income Statement
In the last 12 months, BridgeBio Pharma had revenue of 221.9M
and earned -535.76M
in profits. Earnings per share was -2.88.
| Revenue | 221.9M |
| Gross Profit | 218.02M |
| Operating Income | -592.97M |
| Net Income | -535.76M |
| EBITDA | -436.83M |
| EBIT | -442.9M |
| Earnings Per Share (EPS) | -2.88 |
Full Income StatementBalance Sheet
The company has 681.1M in cash and 1.73B in
debt, giving a net cash position of -1.05B.
| Cash & Cash Equivalents | 681.1M |
| Total Debt | 1.73B |
| Net Cash | -1.05B |
| Retained Earnings | -3.1B |
| Total Assets | 881.64M |
| Working Capital | 543.07M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -520.73M
and capital expenditures -933K, giving a free cash flow of -521.66M.
| Operating Cash Flow | -520.73M |
| Capital Expenditures | -933K |
| Free Cash Flow | -521.66M |
| FCF Per Share | -2.8 |
Full Cash Flow StatementMargins
Gross margin is 98.25%, with operating and profit margins of -267.22% and -241.44%.
| Gross Margin | 98.25% |
| Operating Margin | -267.22% |
| Pretax Margin | -244.34% |
| Profit Margin | -241.44% |
| EBITDA Margin | -196.86% |
| EBIT Margin | -267.22% |
| FCF Margin | -235.09% |
